Clinical Trial Results: A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing nivolumab-relatlimab fixed-dose combination against regorafenib or TAS-102 in later-line metastatic colorectal cancer; study terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Neoplasms

Drugs mentioned

• Nivolumab-relatlimab fixed-dose combination (nivolumab-relatlimab)
• Regorafenib (regorafenib)
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Colorectal Neoplasms | Phase 3 | Status: TERMINATED | Results posted: 2026-08-26